We announced full results from the Phase III CROSSING trial in eosinophilic esophagitis (EoE), a chronic, progressive inflammatory disease where patients can experience persistent burden. Read about the results and our commitment to people living with EoE: bit.ly/4yABXeq

Our new strategic R&D center in Kendall Square, Massachusetts, is now open, bringing together world-class scientists and advanced capabilities to power our pipeline and accelerate the delivery of innovative medicines. Learn more: learn.az/6006BGLoCI

$AZN #WhatScienceCanDo

Today, we announced positive high-level results from our latest Phase III CROSSING trial in people living with eosinophilic esophagitis (EoE), a chronic epithelial-driven inflammatory disease of the esophagus. Read more about the results: bit.ly/4gBH0Eg

We rang the opening bell in a historic moment today at the @NYSE. 

With #AZN trading on the #NYSE, we’re deepening our roots in the US and expanding our access to capital – fueling continued investment in the science behind a healthier America.

Last week, we welcomed the US Ambassador to the UK, Warren Stephens, to The Discovery Center, our global headquarters and state-of-the-art R&D facility in Cambridge.

The visit was a fantastic opportunity to showcase the boundary-pushing science taking place at The DISC, our role in the Cambridge and UK life sciences ecosystem and our deep commitment to the United States.

By deepening the collaboration between the UK and the US, we are accelerating scientific discovery and engaging with governments to deliver the next generation of medicines for patients worldwide.

Today, the FDA has approved a new treatment option for individuals living with hypereosinophilic syndrome (HES), a rare disease driven by elevated eosinophils in the blood, which can lead to progressive organ damage over time. Read more about the approval: bit.ly/3PaNBfn

The FDA just announced the approval of a new way to self-administer therapy for people living with systemic lupus erythematosus (SLE). Learn more: bit.ly/4cIRzDv

Today, we begin trading on the @NYSE. This landmark moment makes it easier for investors to participate in our future and our ambitions to deliver innovative medicines to patients. spr.ly/6015hGnw5 #AZN #NYSE

Rick R. Suarez is appointed Senior Vice President, US President and Head of US BioPharmaceuticals. He will lead the execution of our $50B US R&D and manufacturing investment and the Company’s US BioPharmaceuticals organization. Learn more: spr.ly/6016CUYvK

#News
With @GovWesMoore, we announced plans to invest $2 billion to expand our manufacturing footprint in Maryland, part of our $50 billion investment in the US. This will support 2,600 jobs & accelerate access to innovative therapies. spr.ly/60177m7vW

#News We're establishing a landmark partnership with the Commonwealth of Virginia, Eli Lilly, Merck and Virginia’s higher education institutions to create the largest workforce development hub in the US for advanced pharmaceutical manufacturing: spr.ly/60177HpGt

Today, the FDA approved a new treatment option for chronic rhinosinusitis with nasal polyps (CRSwNP), offering patients an alternative way to help address their symptoms.

Read the full announcement: spr.ly/6014ANDdw

#News Today we announced our plans to invest $4.5 billion in a new manufacturing facility in Virginia. This includes a proposed $500m increase to support enhanced manufacturing capability, driving life sciences innovation and economic growth: spr.ly/6012As4Qw

Today, with @DaiichiSankyoUS, we announced high-level results from the TROPION-Breast02 Phase III trial of our TROP2-directed antibody drug conjugate for 1st-line metastatic triple-negative #breastcancer. Learn more about these data: bit.ly/46NnvoR #AZUS

The FDA has approved a supplemental new drug application for an asthma rescue medication, which now includes clinically meaningful evidence in patients with mild asthma. Discover the implications this announcement has for asthma patients. astrazeneca-us.com/media/press-re…

We’re proud to share promising phase III trial results highlighting our progress toward remission-driven lupus care.

Learn more about the high-level trial results: bit.ly/46pINXQ

Today, we’ve launched a new way to access our FDA-approved influenza vaccine, helping Americans stay protected during the flu season.

Millions get the flu each year, yet vaccination rates continue to decline. Learn more: spr.ly/6011fS2hH

Today, in collaboration with @DaiichiSankyoUS we announced the @US_FDA approval of our treatment for adults with previously treated locally advanced or metastatic EGFR-mutated non-small cell #lungcancer #NSCLC.

Learn more: bit.ly/4kPwv12 #AZUS